Abdullah F Aldasem

Dr. Abdullah F Aldasem

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NANaser Altannak
Naser Altannak
HHHani M Hafez
Hani M Hafez
AHAhmed Hemdan
Ahmed Hemdan
AAAbdullah F Aldasem
Abdullah F Aldasem
IKIbrahim Khadra
Ibrahim Khadra
Background: A novel triple therapy regimen for Helicobacter pylori eradication, recently approved by the U.S. FDA, comprises vonoprazan (VPN), a potassium-competitive acid blocker, in combination with amoxicillin (AMX) and clarithromycin (CMN). This study presents the development and full validation of a rapid, selective, and sensitive LC-MS/MS method for the simultaneous quantification of these three drugs in spiked human plasma. Methods: Sample preparation was performed using a simple and efficient liquid–liquid extraction (LLE) technique. Chromatographic separation was achieved within 5 min using a Phenomenex Kinetex C18 column (100 × 4.6 mm, 2.6 µm) and a gradient elution system consisting of 0.1% formic acid in water and acetonitrile. Moreover, diazepam was used as an internal standard. The mass spectrometric detection was conducted in multiple reaction monitoring (MRM) mode using positive electrospray ionization. Results: The method exhibited excellent linearity over the investigated concentration ranges (2, 5, 10, 20, 50, and 100 ng/mL for amoxicillin and clarithromycin and 5, 10, 20, 30, 50, and 100 ng/mL for vonoprazan). Intra- and inter-day precision and accuracy values met FDA bioanalytical method validation guidelines, with relative standard deviations and relative errors below 15%. Mean absolute recoveries were above 93% for all analytes. Conclusions: The developed method was fully validated, rapid, selective, and sensitive LC-MS/MS and was assessed using the AGREE tool as a greenness assessment approach, confirming its environmental friendliness and alignment with green analytical chemistry principles.

30 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AAAbdullah F Aldasem
Abdullah F Aldasem
Sylvester Nnaemeka UgarioguSylvester Nnaemeka Ugariogu
Sylvester Nnaemeka Ugariogu
AAAbdullah Al-Matrouk
Abdullah Al-Matrouk
NANaser Altannak
Naser Altannak
Semi-synthetic cannabinoids (SSCs) are chemically modified derivatives of naturally occurring phytocannabinoids that have rapidly emerged in commercial cannabis and hemp-derived products, including vape cartridges, edibles, infused oils, and concentrated extracts. Increasing availability of compounds such as hexahydrocannabinol (HHC), HHC analogues, and Δ8-tetrahydrocannabinol (Δ8-THC) has created significant challenges for forensic toxicology, analytical detection, public health surveillance, and regulatory control. This structured narrative review evaluated current evidence on the forensic, toxicological, pharmacological, and analytical implications of SSCs. The literature published between January 2019 and May 2026 was identified through searches of PubMed, Scopus, and Web of Science using predefined search terms related to SSCs, forensic toxicology, analytical detection, intoxication, metabolism, and public health. Recent evidence demonstrates that HHC-related compounds currently dominate the SSC market and scientific literature. Available studies indicate that SSCs undergo extensive Phase I and Phase II metabolism, producing hydroxylated, oxidized, and glucuronidated metabolites that frequently predominate over parent compounds in biological matrices. This metabolic complexity complicates forensic interpretation, particularly in postmortem investigations and impairment assessments where toxicological reference ranges remain poorly established. Emerging intoxication reports describe prolonged sedation, neuropsychiatric manifestations, cognitive impairment, and severe poisoning associated with HHC analogues, although much of the current evidence remains limited to case reports and small observational studies. From an analytical perspective, conventional toxicology screening methods may fail to detect SSC exposure, necessitating advanced analytical approaches such as liquid chromatography–tandem mass spectrometry (LC–MS/MS), high-resolution mass spectrometry (HRMS), and chiral chromatographic techniques for metabolite identification and epimer differentiation. However, limited reference standards, evolving structural diversity, and regulatory variability across jurisdictions continue to hinder standardized detection and interpretation. Overall, SSCs represent a rapidly evolving class of psychoactive compounds requiring coordinated advancements in forensic toxicology, analytical surveillance, pharmacological characterization, and public health monitoring to improve detection reliability, risk assessment, and regulatory response.